Aspen Pharmacare (APN) – Growing Pains

We believe supply chain issues will continue to plague Aspen (APN) going into FY18. We provide evidence that the anaesthetics portfolio’s growth prospects may be hampered in 2H18. A look at the search interest trends of APN’s products, provides interesting insights into growth opportunities for the company.